Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 8/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.68 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.68 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.63 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.61 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465101 | 1.00 | P2RX3 (0.68) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL30023799 | 1.00 | P2RX3 (0.68) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL23748621 | 0.92 | P2RX3 (0.67) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL29511147 | 0.92 | P2RX3 (0.67) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL16777543 | 0.91 | P2RX3 (0.66) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL26027907 | 0.91 | P2RX3 (0.66) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL22837322 | 0.91 | P2RX3 (0.66) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL16777585 | 0.91 | P2RX3 (0.66) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL22837327 | 0.90 | P2RX1 (0.64) | P2RX3P2RX1P2RX2P2RY1P2RX4 | |
| SCHEMBL16640135 | 0.90 | P2RX3 (0.67) | P2RX3P2RX1P2RX2P2RY1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12077558-B2 | Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-06 | — | — | US | disclosed |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
| WO-2021146391-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C–P BONDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-3774824-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-24 | — | — | US | disclosed |
| WO-2019200273-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | P2RX3 1431/4885P2RX1 1240/4885P2RX2 1490/4885 |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | P2RX3 552/4885P2RX1 672/4885P2RX2 444/4885 |
| US-12077558-B2 | Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds | PPIP5K2, PLCB3, PLCG2 | P2RX3 337/4885P2RX1 418/4885P2RX2 322/4885 |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | PPIP5K2, INPP5B, PTMS | P2RX3 552/4885P2RX1 672/4885P2RX2 444/4885 |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | P2RX3 420/4885P2RX1 565/4885P2RX2 360/4885 |
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | PNKP, POLL, RNGTT | P2RX3 2478/4885P2RX1 2454/4885P2RX2 2155/4885 |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | PNKP, POLL, RNGTT | P2RX3 2326/4885P2RX1 2268/4885P2RX2 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.